Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s amcenestrant in ER+ patients who prematurely discontinue ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 06, 2021
Lead Product(s) : Amcenestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 20, 2016
Lead Product(s) : Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : ETOP IBCSG Partners Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2015
Lead Product(s) : Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : ETOP IBCSG Partners Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : ETOP IBCSG Partners Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 02, 2014
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : ETOP IBCSG Partners Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2014
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : ETOP IBCSG Partners Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 10, 2012
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : ETOP IBCSG Partners Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
